-
1
-
-
12244262297
-
Pharmacokinetic-pharmacodynamic analysis of lopinavir-ritonavir in combination with efavirenz and two nucleoside reverse transcriptase inhibitors in extensively pretreated human immunodeficiency virus-infected patients
-
Hsu A, Isaacson J, Brun S, et al. Pharmacokinetic-pharmacodynamic analysis of lopinavir-ritonavir in combination with efavirenz and two nucleoside reverse transcriptase inhibitors in extensively pretreated human immunodeficiency virus-infected patients. Antimicrob Agents Chemother 2003; 47: 350-9.
-
(2003)
Antimicrob Agents Chemother
, vol.47
, pp. 350-359
-
-
Hsu, A.1
Isaacson, J.2
Brun, S.3
-
2
-
-
32644481286
-
Biks Study (Lopinavir/Ritonavir-Efavirenz combination): Complete 24-week results
-
Ferré V, Allavena C, Poizot-Martin I, et al. Biks Study (Lopinavir/Ritonavir-Efavirenz combination): complete 24-week results. Antivir Ther 2003; 8(Suppl 1): S193.
-
(2003)
Antivir Ther
, vol.8
, Issue.SUPPL. 1
-
-
Ferré, V.1
Allavena, C.2
Poizot-Martin, I.3
-
3
-
-
11144357775
-
Therapeutic drug monitoring of lopinavir/ritonavir given alone or with a non-nucleoside reverse transcriptase inhibitor
-
Solas C, Poizot-Martin I, Drogoul MP, et al. Therapeutic drug monitoring of lopinavir/ritonavir given alone or with a non-nucleoside reverse transcriptase inhibitor. Br J Clin Pharmacol 2004; 57: 436-40.
-
(2004)
Br J Clin Pharmacol
, vol.57
, pp. 436-440
-
-
Solas, C.1
Poizot-Martin, I.2
Drogoul, M.P.3
-
4
-
-
12244262297
-
Pharmacokinetic-pharmacodynamic analysis of lopinavir-ritonavir in combination with efavirenz and two nucleoside reverse transcriptase inhibitors in extensively pretreated human immunodeficiency virus-infected patients
-
Hsu A, Isaacson J, Brun S, et al. Pharmacokinetic-pharmacodynamic analysis of lopinavir-ritonavir in combination with efavirenz and two nucleoside reverse transcriptase inhibitors in extensively pretreated human immunodeficiency virus-infected patients. Antimicrob Agents Chemother 2003; 47: 350-9.
-
(2003)
Antimicrob Agents Chemother
, vol.47
, pp. 350-359
-
-
Hsu, A.1
Isaacson, J.2
Brun, S.3
-
5
-
-
8844242515
-
Determination of atazanavir and other antiretroviral drugs (indinavir, amprenavir, nelfinavir and its active metabolite M8, saquinavir, ritonavir, lopinavir, nevirapine and efavirenz) plasma levels by high performance liquid chromatography with UV detection
-
in press
-
Dailly E, Raffi F, Jolliet P. Determination of atazanavir and other antiretroviral drugs (indinavir, amprenavir, nelfinavir and its active metabolite M8, saquinavir, ritonavir, lopinavir, nevirapine and efavirenz) plasma levels by high performance liquid chromatography with UV detection. J Chromatogr B Biomed Sci Appl 2004; in press.
-
(2004)
J Chromatogr B Biomed Sci Appl
-
-
Dailly, E.1
Raffi, F.2
Jolliet, P.3
-
6
-
-
32644467475
-
Interactions des antirétroviraux
-
eds. Dariosecq JM, Taburet AM, Girard PM. Rueil-Malmaison: Doin
-
Dariosecq JM, Taburet AM, Girard PM. Interactions des antirétroviraux. In: The Infection VIH - Mémento Thérapeutique, 6th edn, eds. Dariosecq JM, Taburet AM, Girard PM. Rueil-Malmaison: Doin 2003; 134-205.
-
(2003)
The Infection VIH - Mémento Thérapeutique, 6th Edn.
, pp. 134-205
-
-
Dariosecq, J.M.1
Taburet, A.M.2
Girard, P.M.3
-
7
-
-
0036162141
-
The influence of efavirenz on the pharmacokinetics of a twice-daily combination of indinavir and low-dose ritonavir in healthy volunteers
-
Aarnoutse RE, Grintjes KJ, Telgt DS, et al. The influence of efavirenz on the pharmacokinetics of a twice-daily combination of indinavir and low-dose ritonavir in healthy volunteers. Clin Pharmacol Ther 2002; 71: 57-67.
-
(2002)
Clin Pharmacol Ther
, vol.71
, pp. 57-67
-
-
Aarnoutse, R.E.1
Grintjes, K.J.2
Telgt, D.S.3
|